ICOS Antibody (27A12) is a hamster monoclonal IgM antibody that detects ICOS in mouse samples through flow cytometry (FCM). ICOS, or inducible co-stimulator, plays a crucial role in the immune response by enhancing T cell activation and promoting the production of interleukin-10, a cytokine that helps regulate immune responses and maintain tolerance. ICOS is primarily expressed on activated T cells and is essential for the development of effective immune responses, particularly in the context of T cell interactions with antigen-presenting cells. Anti-ICOS antibody (27A12) enables researchers to study ICOS′s ability to fine-tune T cell activity, ensuring that the immune system can respond robustly to pathogens while preventing excessive inflammation that could lead to tissue damage. ICOS monoclonal antibody (27A12) provides valuable insights into T cell dynamics and the mechanisms underlying immune regulation, making this tool indispensable for studies focused on immunology and therapeutic interventions.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
ICOS Antibody (27A12) References:
- ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity. | Maazi, H., et al. 2015. Immunity. 42: 538-51. PMID: 25769613
- IL-6 and ICOS Antagonize Bim and Promote Regulatory T Cell Accrual with Age. | Raynor, J., et al. 2015. J Immunol. 195: 944-52. PMID: 26109645
- ICOS-Ligand Triggering Impairs Osteoclast Differentiation and Function In Vitro and In Vivo. | Gigliotti, CL., et al. 2016. J Immunol. 197: 3905-3916. PMID: 27798154
- Protective Role of ICOS and ICOS Ligand in Corneal Transplantation and in Maintenance of Immune Privilege. | Kunishige, T., et al. 2016. Invest Ophthalmol Vis Sci. 57: 6815-6823. PMID: 28002569
- ICOS Signaling Controls Induction and Maintenance of Collagen-Induced Arthritis. | Panneton, V., et al. 2018. J Immunol. 200: 3067-3076. PMID: 29581356
- ICOS deficiency hampers the homeostasis, development and function of NK cells. | Montes-Casado, M., et al. 2019. PLoS One. 14: e0219449. PMID: 31283790
- The ubiquitin ligase Peli1 inhibits ICOS and thereby Tfh-mediated immunity. | Huang, X., et al. 2021. Cell Mol Immunol. 18: 969-978. PMID: 33707688
- ICOS ligand and IL-10 synergize to promote host-microbiota mutualism. | Landuyt, AE., et al. 2021. Proc Natl Acad Sci U S A. 118: PMID: 33753483
- Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models. | Orvain, C., et al. 2022. Arthritis Res Ther. 24: 13. PMID: 34986869
- Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression. | Lv, Y., et al. 2024. J Adv Res. 57: 149-162. PMID: 37086778